Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma | Zendy

Michael Schaapveld | Zendy; Berthe M.P. Aleman | Zendy; Anna M. van Eggermond | Zendy; Cècile P.M. Janus | Zendy; Augustinus D. G. Krol | Zendy; Richard W.M. van der Maazen | Zendy; Judith M. Roesink | Zendy; John Raemaekers | Zendy; Jan Paul de Boer | Zendy; Josée M. Zijlstra | Zendy; Gustaaf W. van Imhoff | Zendy; Eefke Petersen | Zendy; Philip Poortmans | Zendy; Max Beijert | Zendy; Marnix L.M. Lybeert | Zendy; Ina Mulder | Zendy; Otto Visser | Zendy; Marieke W.J. Louwman | Zendy; Inge M. Krul | Zendy; Pieternella J. Lugtenburg | Zendy; Flora E. van Leeuwen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Second Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma

Author(s) -

Michael Schaapveld,

Berthe M.P. Aleman,

Anna M. van Eggermond,

Cècile P.M. Janus,

Augustinus D. G. Krol,

Richard W.M. van der Maazen,

Judith M. Roesink,

John Raemaekers,

Jan Paul de Boer,

Josée M. Zijlstra,

Gustaaf W. van Imhoff,

Eefke Petersen,

Philip Poortmans,

Max Beijert,

Marnix L.M. Lybeert,

Ina Mulder,

Otto Visser,

Marieke W.J. Louwman,

Inge M. Krul,

Pieternella J. Lugtenburg,

Flora E. van Leeuwen

Publication year - 2015

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1505949

Subject(s) - medicine , incidence (geometry) , population , cancer , cohort , cumulative incidence , standardized mortality ratio , breast cancer , relative risk , non hodgkin's lymphoma , confidence interval , cohort study , cancer registry , lymphoma , surgery , physics , environmental health , optics

Survivors of Hodgkin's lymphoma are at increased risk for treatment-related subsequent malignant neoplasms. The effect of less toxic treatments, introduced in the late 1980s, on the long-term risk of a second cancer remains unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research